Developer docs
API playgroundTry for free, no card

Search company profiles

Scribe Therapeutics

Full company profile

uuid00003ce

Namestring
Scribe Therapeutics
Legal namestring
Scribe Therapeutics
Websiteurl
scribetx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Scribe Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Alameda, California, that engineers CRISPR-based genetic medicines for cardiometabolic and other high-burden diseases. The company's technology foundation consists of two proprietary platforms built on engineered CasX-derived proteins: X-Editor (XE), a gene editing platform that delivers >100x higher activity than naturally occurring CasX with no detectable off-targets at >75% liver editing in NHPs, and ELXR (Epigenetic Long-Term X-Repressor), a nuclease-inactivated system fused to epigenetic effector domains that durably silences gene expression without permanently altering DNA, supported by allosteric regulation. An internal AI tool, DeepXE, reduces guide RNA screening burden by 50%. The lead wholly-owned asset, STX-1150, is an ELXR-based therapy delivered via lipid nanoparticles to silence PCSK9 in the liver for durable LDL-C reduction; it received Australian TGA clearance in May 2026 and entered a first-in-human Phase 1 study in Australia and New Zealand. Two additional preclinical wholly-owned programs (STX-1200 targeting LPA for Lp(a) lowering and STX-1400 targeting APOC3 for triglyceride reduction) are funded by a >$25M CIRM award from June 2026.

Scribe's business model is a partnership-driven biotech model: the company monetizes its XE and ELXR platforms through co-development and licensing deals with major pharmaceutical companies rather than through direct product sales. Active partners include Eli Lilly (via Prevail Therapeutics) for neurological and neuromuscular diseases (>$1.5B in potential milestones plus tiered royalties), Sanofi for in vivo sickle cell and genomic diseases (>$1.2B in potential milestones) and for ex vivo NK cell oncology therapies (>$1B potential), and Biogen for ALS. Scribe retains co-funding and co-promotion/profit-sharing options on select US programs, and the company reported $51.2M in collaboration revenue for FY2025. The company is privately held, backed by a16z, OrbiMed, Avoro Ventures, Wellington Management, Perceptive Advisors, Menlo Ventures, T. Rowe Price, and RaCapital, and filed for a Nasdaq IPO under ticker SCTX in July 2026 targeting up to $75M. Scientific leadership is anchored by co-founder Jennifer Doudna (CRISPR co-discoverer and Nobel laureate) and a co-founding team of Benjamin Oakes (CEO), David Savage, and Brett Staahl, all with deep UC Berkeley roots.

Short descriptiontext

Scribe Therapeutics is a clinical-stage biotech developing CRISPR-based genetic medicines using proprietary X-Editor (XE) and ELXR platforms, initially targeting cardiometabolic disease with single-dose, durable therapies delivered via lipid nanoparticles.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, epigenetic silencing therapy, genetic medicine development, cardiometabolic therapeutics, biologics drug discovery
Industry4 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Genetic Medicines
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Collaboration Payments
TypeLicensing Royalties
Description

Upfront payments, equity investments, R&D funding, milestone payments, and tiered royalties from pharmaceutical partnerships with Sanofi and Eli Lilly/Prevail. Reported $51.2M in collaboration revenue for FY2025.

ainvest.com
2Government Grants
TypeProfessional Services
Description

CIRM awards ($25M+) for preclinical development of cardiometabolic gene editing programs STX-1200 and STX-1400.

longevity.technology
3IPO Proceeds
TypeOne Time License
Description

Planned Nasdaq IPO targeting up to $75 million to fund clinical development of cardiometabolic pipeline.

thepharmaletter.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Scribe Therapeutics is a clinical-stage biotechnology company that engineers CRISPR-based genetic medicines for cardiometabolic disease. The company develops therapeutic candidates using two proprietary platforms—X-Editor (XE), an engineered CRISPR-CasX-based gene editing system, and ELXR (Epigenetic Long-Term X-Repressor), a reversible epigenetic silencing technology—supported by the DeepXE AI design platform for guide RNA optimization. Lead candidate STX-1150 targets PCSK9 for LDL-C lowering and is in Phase 1 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Single dose of STX-1150 achieved >50% LDL-C reduction sustained for >22 months in non-human primates
+5 more records
Product overview1 text field

Scribe Therapeutics is a clinical-stage biotechnology company developing CRISPR-based genetic medicines for cardiometabolic disease. The company offers two core technology platforms: X-Editor (XE) for gene editing and Epigenetic Long-Term X-Repressor (ELXR) for epigenetic silencing. The proprietary CRISPR by Design approach engineers bacterial immune systems into therapeutically relevant genome editing tools. The clinical-stage pipeline includes STX-1150 (PCSK9 silencing for LDL-C lowering), while preclinical programs include STX-1200 (LPA targeting for Lp(a) lowering) and STX-1400 (APOC3 targeting for triglyceride lowering). The company has strategic collaborations with Sanofi and Eli Lilly/Prevail Therapeutics for additional therapeutic programs.

Product and service6 records
1STX-1150
CategoryClinical-stage therapeutic candidate
Description

A clinical-stage liver-targeted CRISPR-based epigenetic silencing therapy that uses ELXR technology delivered via lipid nanoparticles to durably reduce LDL-C by silencing the PCSK9 gene without permanently altering DNA. Designed for adults with elevated LDL-C at increased cardiovascular risk.

2STX-1200
CategoryPreclinical therapeutic candidate
Description

A preclinical CRISPR-based gene editing therapy that uses X-Editor (XE) technology to target the LPA gene to reduce lipoprotein(a) [Lp(a)] for treatment and prevention of atherosclerotic cardiovascular disease in patients with genetically elevated Lp(a).

3STX-1400
CategoryPreclinical therapeutic candidate
Description

A preclinical CRISPR-based gene editing therapy using X-Editor (XE) technology that targets APOC3 to lower triglyceride-rich lipoproteins for addressing acute pancreatitis in triglyceride-driven diseases such as familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS).

4X-Editor (XE) Platform
CategoryTechnology platform (licensed)
Description

A proprietary CRISPR-based gene editing technology using a staggered DNA cleavage mechanism with >100-fold higher editing activity than naturally occurring CasX. Supports gene knock-out, knock-down, knock-in, exon skipping, and genetic excision. Licensed to pharmaceutical partners for therapeutic development.

5ELXR (Epigenetic Long-Term X-Repressor) Platform
CategoryTechnology platform (licensed)
Description

A proprietary CRISPR-based epigenetic silencing technology built on nuclease-inactivated engineered CasX fused to epigenetic effector domains with allosteric regulation for enhanced specificity. Enables durable yet reversible gene silencing without altering DNA. Licensed to pharmaceutical partners for therapeutic development.

6DeepXE AI Design Platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

CIRM awarded Scribe more than $25 million across two preclinical programs (STX-1200 for Lp(a) lowering and STX-1400 for triglyceride reduction) through its Preclinical Development Program to advance CRISPR-based gene editing therapies toward clinical trials in California.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-07-17
Description

Expanded collaboration for in vivo genetic medicines targeting sickle cell disease and other genomic diseases using Scribe's CRISPR XE technologies with Sanofi's non-viral delivery. Scribe receives $40M upfront with potential milestones exceeding $1.2B and tiered royalties (high single digits to low double digits). Scribe has co-promotion/profit sharing option on one US program. Sanofi also exercised option for second in vivo target in January 2024. Companies achieved first success milestone in January 2025.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-05-16
Description

Strategic collaboration to develop in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. Scribe grants exclusive rights to its CRISPR X-Editing technologies for specified targets. Scribe receives $75M upfront and equity investment, with potential milestones exceeding $1.5B and tiered royalties into low double-digits. Scribe retains option to co-fund and share profits on one US program. Two success milestones achieved as of February 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Initial collaboration granting Sanofi non-exclusive license to CRISPR by Design platform and CasX-Editor technology for developing engineered NK cell therapies for multiple oncology indications. Scribe receives $25M upfront with potential milestones exceeding $1B plus tiered royalties.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Licensor of liver-tropic lipid nanoparticle (LNP) delivery technology used to encapsulate STX-1150's mRNA encoding ELXR and guide RNA for liver-targeted PCSK9 targeting. LNP delivery enables efficient hepatocyte uptake for epigenetic silencing therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Research collaboration to develop CRISPR-based therapies for ALS. Biogen exercised option for an additional disease target in 2025, expanding the collaboration. Focus on neurological disorders with potential for in vivo CNS editing using Scribe's XE technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Co-founded by Nobel laureate Jennifer Doudna; Scribe was co-founded based on science from this institute. Provides scientific collaboration and academic partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Academic institution where co-founders Jennifer Doudna, David Savage, and Benjamin Oakes conducted foundational CRISPR research. Primary source of Scribe's core technology and scientific talent.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage biotech developing in vivo gene editing medicines for cardiovascular disease, including a lead PCSK9 program (VERVE-101) targeting the same LDL-C indication as Scribe's STX-1150. Most directly comparable peer given shared indication, base-editing/in vivo editing approach, and partnership model.

TypeDirect peer
Description

Clinical-stage CRISPR/Cas9 gene editing company developing both in vivo (liver, including transthyretin amyloidosis) and ex vivo (oncology) programs. Closely comparable platform stage and modality mix, with ongoing partnerships with Regeneron and Novartis.

TypeDirect peer
Description

First company to commercialize a CRISPR-based therapy (Casgevy for sickle cell disease) via partnership with Vertex. Directly comparable in vivo and ex vivo pipeline, with overlapping sickle cell and cardiometabolic programs.

TypeDirect peer
Description

Clinical-stage gene editing company developing CRISPR-based medicines, including Casgevy co-developer with a sickle cell program overlapping Scribe's Sanofi-partnered indication. Comparable platform orientation and stage.

TypeDirect peer
Description

Clinical-stage biotech developing base editing medicines, including cardiovascular programs (e.g., BEAM-301 for GSD1a) and a partnered sickle cell program with Pfizer. Highly comparable modality (precision gene editing) and target overlap.

TypeDirect peer
Description

Clinical-stage company developing prime editing therapies with both wholly-owned and partnered programs. Comparable platform-stage CRISPR-derived modality, with overlap in chronic and rare disease indications.

TypeBroad incumbent
Description

Pioneer in genome engineering (zinc finger, AAV-based) with clinical-stage programs in cardiometabolic and rare diseases including a partnered PCSK9 program with Eli Lilly. Broader incumbent in the gene editing/genome engineering space with overlap in cardiovascular targets.

TypeEmerging player
Description

Clinical-stage CRISPR genome editing company with allogeneic CAR-T and iPSC-derived NK cell programs. Partial overlap with Scribe's ex vivo NK cell collaboration with Sanofi, and similar platform-stage orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scribe Therapeutics

Genetic Medicinesscribetx.com

Scribe Therapeutics is a clinical-stage biotech developing CRISPR-based genetic medicines using proprietary X-Editor (XE) and ELXR platforms, initially targeting cardiometabolic disease with single-dose, durable therapies delivered via lipid nanoparticles.

What Scribe Therapeutics does

Scribe Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Alameda, California, that engineers CRISPR-based genetic medicines for cardiometabolic and other high-burden diseases. The company's technology foundation consists of two proprietary platforms built on engineered CasX-derived proteins: X-Editor (XE), a gene editing platform that delivers >100x higher activity than naturally occurring CasX with no detectable off-targets at >75% liver editing in NHPs, and ELXR (Epigenetic Long-Term X-Repressor), a nuclease-inactivated system fused to epigenetic effector domains that durably silences gene expression without permanently altering DNA, supported by allosteric regulation. An internal AI tool, DeepXE, reduces guide RNA screening burden by 50%. The lead wholly-owned asset, STX-1150, is an ELXR-based therapy delivered via lipid nanoparticles to silence PCSK9 in the liver for durable LDL-C reduction; it received Australian TGA clearance in May 2026 and entered a first-in-human Phase 1 study in Australia and New Zealand. Two additional preclinical wholly-owned programs (STX-1200 targeting LPA for Lp(a) lowering and STX-1400 targeting APOC3 for triglyceride reduction) are funded by a >$25M CIRM award from June 2026.

Scribe's business model is a partnership-driven biotech model: the company monetizes its XE and ELXR platforms through co-development and licensing deals with major pharmaceutical companies rather than through direct product sales. Active partners include Eli Lilly (via Prevail Therapeutics) for neurological and neuromuscular diseases (>$1.5B in potential milestones plus tiered royalties), Sanofi for in vivo sickle cell and genomic diseases (>$1.2B in potential milestones) and for ex vivo NK cell oncology therapies (>$1B potential), and Biogen for ALS. Scribe retains co-funding and co-promotion/profit-sharing options on select US programs, and the company reported $51.2M in collaboration revenue for FY2025. The company is privately held, backed by a16z, OrbiMed, Avoro Ventures, Wellington Management, Perceptive Advisors, Menlo Ventures, T. Rowe Price, and RaCapital, and filed for a Nasdaq IPO under ticker SCTX in July 2026 targeting up to $75M. Scientific leadership is anchored by co-founder Jennifer Doudna (CRISPR co-discoverer and Nobel laureate) and a co-founding team of Benjamin Oakes (CEO), David Savage, and Brett Staahl, all with deep UC Berkeley roots.

Scribe Therapeutics firmographics

Firmographics
Name
Scribe Therapeutics
Legal name
Scribe Therapeutics
Website
https://scribetx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Scribe Therapeutics is a clinical-stage biotech developing CRISPR-based genetic medicines using proprietary X-Editor (XE) and ELXR platforms, initially targeting cardiometabolic disease with single-dose, durable therapies delivered via lipid nanoparticles.
Ownership category
akta.pro rank

Scribe Therapeutics industry classification

Industry
Product category
Genetic Medicines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • CRISPR gene editing
  • Epigenetic silencing therapy
  • Genetic medicine development
  • Cardiometabolic therapeutics
  • Biologics drug discovery

Where Scribe Therapeutics is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Scribe Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Strategic Collaboration Payments: Upfront payments, equity investments, R&D funding, milestone payments, and tiered royalties from pharmaceutical partnerships with Sanofi and Eli Lilly/Prevail. Reported $51.2M in collaboration revenue for FY2025.
  2. Government Grants: CIRM awards ($25M+) for preclinical development of cardiometabolic gene editing programs STX-1200 and STX-1400.
  3. IPO Proceeds: Planned Nasdaq IPO targeting up to $75 million to fund clinical development of cardiometabolic pipeline.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Scribe Therapeutics product offering

Product offering

Core offering

Scribe Therapeutics is a clinical-stage biotechnology company that engineers CRISPR-based genetic medicines for cardiometabolic disease. The company develops therapeutic candidates using two proprietary platforms—X-Editor (XE), an engineered CRISPR-CasX-based gene editing system, and ELXR (Epigenetic Long-Term X-Repressor), a reversible epigenetic silencing technology—supported by the DeepXE AI design platform for guide RNA optimization. Lead candidate STX-1150 targets PCSK9 for LDL-C lowering and is in Phase 1 clinical trials.

Product overview

Scribe Therapeutics is a clinical-stage biotechnology company developing CRISPR-based genetic medicines for cardiometabolic disease. The company offers two core technology platforms: X-Editor (XE) for gene editing and Epigenetic Long-Term X-Repressor (ELXR) for epigenetic silencing. The proprietary CRISPR by Design approach engineers bacterial immune systems into therapeutically relevant genome editing tools. The clinical-stage pipeline includes STX-1150 (PCSK9 silencing for LDL-C lowering), while preclinical programs include STX-1200 (LPA targeting for Lp(a) lowering) and STX-1400 (APOC3 targeting for triglyceride lowering). The company has strategic collaborations with Sanofi and Eli Lilly/Prevail Therapeutics for additional therapeutic programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • STX-1150 A clinical-stage liver-targeted CRISPR-based epigenetic silencing therapy that uses ELXR technology delivered via lipid nanoparticles to durably reduce LDL-C by silencing the PCSK9 gene without permanently altering DNA. Designed for adults with elevated LDL-C at increased cardiovascular risk.
  • STX-1200 A preclinical CRISPR-based gene editing therapy that uses X-Editor (XE) technology to target the LPA gene to reduce lipoprotein(a) [Lp(a)] for treatment and prevention of atherosclerotic cardiovascular disease in patients with genetically elevated Lp(a).
  • STX-1400 A preclinical CRISPR-based gene editing therapy using X-Editor (XE) technology that targets APOC3 to lower triglyceride-rich lipoproteins for addressing acute pancreatitis in triglyceride-driven diseases such as familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS).
  • X-Editor (XE) Platform A proprietary CRISPR-based gene editing technology using a staggered DNA cleavage mechanism with >100-fold higher editing activity than naturally occurring CasX. Supports gene knock-out, knock-down, knock-in, exon skipping, and genetic excision. Licensed to pharmaceutical partners for therapeutic development.
  • ELXR (Epigenetic Long-Term X-Repressor) Platform A proprietary CRISPR-based epigenetic silencing technology built on nuclease-inactivated engineered CasX fused to epigenetic effector domains with allosteric regulation for enhanced specificity. Enables durable yet reversible gene silencing without altering DNA. Licensed to pharmaceutical partners for therapeutic development.
  • DeepXE AI Design Platform

Quantifiable outcome

  • Single dose of STX-1150 achieved >50% LDL-C reduction sustained for >22 months in non-human primates
  • +5 more outcomes

Companies that use Scribe Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Scribe Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scribe Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and flagship.

  • California Institute for Regenerative Medicine (CIRM)coreStrategic or Co-development Partner · 18 June 2026CIRM awarded Scribe more than $25 million across two preclinical programs (STX-1200 for Lp(a) lowering and STX-1400 for triglyceride reduction) through its Preclinical Development Program to advance CRISPR-based gene editing therapies toward clinical trials in California.
  • SanofiflagshipStrategic or Co-development Partner · 17 July 2023Expanded collaboration for in vivo genetic medicines targeting sickle cell disease and other genomic diseases using Scribe's CRISPR XE technologies with Sanofi's non-viral delivery. Scribe receives $40M upfront with potential milestones exceeding $1.2B and tiered royalties (high single digits to low double digits). Scribe has co-promotion/profit sharing option on one US program. Sanofi also exercised option for second in vivo target in January 2024. Companies achieved first success milestone in January 2025.
  • Eli Lilly (Prevail Therapeutics)flagshipStrategic or Co-development Partner · 16 May 2023Strategic collaboration to develop in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. Scribe grants exclusive rights to its CRISPR X-Editing technologies for specified targets. Scribe receives $75M upfront and equity investment, with potential milestones exceeding $1.5B and tiered royalties into low double-digits. Scribe retains option to co-fund and share profits on one US program. Two success milestones achieved as of February 2026.
  • Sanofi (NK Cell Therapy)coreStrategic or Co-development Partner · 1 January 2022Initial collaboration granting Sanofi non-exclusive license to CRISPR by Design platform and CasX-Editor technology for developing engineered NK cell therapies for multiple oncology indications. Scribe receives $25M upfront with potential milestones exceeding $1B plus tiered royalties.
  • Acuitas TherapeuticscoreTechnology or Integration · 1 January 2021Licensor of liver-tropic lipid nanoparticle (LNP) delivery technology used to encapsulate STX-1150's mRNA encoding ELXR and guide RNA for liver-targeted PCSK9 targeting. LNP delivery enables efficient hepatocyte uptake for epigenetic silencing therapy.
  • BiogencoreStrategic or Co-development Partner · 1 January 2020Research collaboration to develop CRISPR-based therapies for ALS. Biogen exercised option for an additional disease target in 2025, expanding the collaboration. Focus on neurological disorders with potential for in vivo CNS editing using Scribe's XE technology.
  • Innovative Genomics InstitutecoreStrategic or Co-development Partner · 1 January 2017Co-founded by Nobel laureate Jennifer Doudna; Scribe was co-founded based on science from this institute. Provides scientific collaboration and academic partnership.
  • UC BerkeleycoreStrategic or Co-development Partner · 1 January 2017Academic institution where co-founders Jennifer Doudna, David Savage, and Benjamin Oakes conducted foundational CRISPR research. Primary source of Scribe's core technology and scientific talent.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Scribe Therapeutics competitors and assessment

Company assessment

Direct peers

  • Verve Therapeutics: Clinical-stage biotech developing in vivo gene editing medicines for cardiovascular disease, including a lead PCSK9 program (VERVE-101) targeting the same LDL-C indication as Scribe's STX-1150. Most directly comparable peer given shared indication, base-editing/in vivo editing approach, and partnership model.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing both in vivo (liver, including transthyretin amyloidosis) and ex vivo (oncology) programs. Closely comparable platform stage and modality mix, with ongoing partnerships with Regeneron and Novartis.
  • CRISPR Therapeutics: First company to commercialize a CRISPR-based therapy (Casgevy for sickle cell disease) via partnership with Vertex. Directly comparable in vivo and ex vivo pipeline, with overlapping sickle cell and cardiometabolic programs.
  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based medicines, including Casgevy co-developer with a sickle cell program overlapping Scribe's Sanofi-partnered indication. Comparable platform orientation and stage.
  • Beam Therapeutics: Clinical-stage biotech developing base editing medicines, including cardiovascular programs (e.g., BEAM-301 for GSD1a) and a partnered sickle cell program with Pfizer. Highly comparable modality (precision gene editing) and target overlap.
  • Prime Medicine: Clinical-stage company developing prime editing therapies with both wholly-owned and partnered programs. Comparable platform-stage CRISPR-derived modality, with overlap in chronic and rare disease indications.

Broad incumbents

  • Sangamo Therapeutics: Pioneer in genome engineering (zinc finger, AAV-based) with clinical-stage programs in cardiometabolic and rare diseases including a partnered PCSK9 program with Eli Lilly. Broader incumbent in the gene editing/genome engineering space with overlap in cardiovascular targets.

Emerging players

  • Caribou Biosciences: Clinical-stage CRISPR genome editing company with allogeneic CAR-T and iPSC-derived NK cell programs. Partial overlap with Scribe's ex vivo NK cell collaboration with Sanofi, and similar platform-stage orientation.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Scribe Therapeutics social profiles

Digital presence

Scribe Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scribe Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Scribe Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scribe Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scribe Therapeutics

What does Scribe Therapeutics do?

Scribe Therapeutics is a clinical-stage biotechnology company that engineers CRISPR-based genetic medicines for cardiometabolic disease. The company develops therapeutic candidates using two proprietary platforms—X-Editor (XE), an engineered CRISPR-CasX-based gene editing system, and ELXR (Epigenetic Long-Term X-Repressor), a reversible epigenetic silencing technology—supported by the DeepXE AI design platform for guide RNA optimization. Lead candidate STX-1150 targets PCSK9 for LDL-C lowering and is in Phase 1 clinical trials.

Is Scribe Therapeutics a public or private company?

Scribe Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scribe Therapeutics founded?

Scribe Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Scribe Therapeutics based?

Scribe Therapeutics is headquartered in Alameda, United States, in the North America region.

How does Scribe Therapeutics make money?

Three revenue lines are on record. Strategic Collaboration Payments are the primary driver. The others are government Grants and IPO Proceeds.

Who are Scribe Therapeutics's main competitors?

Direct peers on record are Verve Therapeutics, Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics and Prime Medicine. Sangamo Therapeutics is listed as a broad incumbent. Caribou Biosciences is listed as an emerging player.

Does Scribe Therapeutics have an API?

No public API is recorded for Scribe Therapeutics.

What industry is Scribe Therapeutics in?

Scribe Therapeutics's product category is Genetic Medicines. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comScribe reports preclinical data on cholesterol therapiesScribe Therapeutics presented preclinical data on its STX-1150 and STX-1200 cholesterol therapies at the American Heart Association Scientific Sessions 2026. STX-1150 reduced LDL cholesterol by over 50% for two years in non-human primates, while STX-1200 achieved over 95% reduction in apolipoprotein(a). The company expects initial clinical data from its Phase 1 trial in the first half of 2027.The future of tradingScribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026Scribe Therapeutics presented preclinical data at AHA 2026 showing its STX-1150 prototype lowered LDL-C by over 50% for at least two years in non-human primates after a single dose, and its STX-1200 surrogate achieved over 95% Lp(a) reduction. The data support ultra-long-acting genetic medicines for cardiovascular disease, with initial clinical data for STX-1150 expected in the first half of 2027.Investing.comCathie Wood’s ARK sells BYD stock, buys Kratos DefenseARK ETF sold 219,468 BYD shares for $1.865 million and bought 24,784 Kratos Defense shares for $861,244. It also acquired 28,905 Scribe Therapeutics shares for $491,095 and divested 7,996 Tempus AI shares for $606,816.Seeking AlphaScribe Therapeutics Inc. GAAP EPS of -$0.68 beats by $0.20, revenue of $1.6M misses by $2.12MScribe Therapeutics reported Q3 GAAP EPS of -$0.68, beating estimates by $0.20, but revenue of $1.6M missed by $2.12M. The company's stock closed at $16.99, up 0.77%.Stock TitanScribe Therapeutics Q3 earnings: net loss rises to $9.9MScribe Therapeutics reported a Q3 2026 net loss of $9.9 million, up from $6.5 million in Q2. Cash and marketable securities stood at $174.2 million as of September 30, 2026, providing funding into the first half of 2029. The company also expanded its Sanofi collaboration to include ELXR epigenetic silencing technology.Longevity.TechnologyScribe’s one-dose approach keeps cholesterol down for yearsScribe Therapeutics presented preclinical data on STX-1150 and STX-1200 at the AHA Scientific Sessions in Chicago. One dose of STX-1150 kept LDL cholesterol under control for at least two years in non-human primates. The company is open to conversations with prospective partners and investors.Business & FinancialScribe Therapeutics Reports Third Quarter 2026 Financial Results And Recent Corporate HighlightsScribe Therapeutics reported Q3 2026 results, with a net loss of $9.9 million and cash of $174.2 million. The company raised $155.5 million from its IPO and private placement, funding operations into the first half of 2029. It also expanded its Sanofi collaboration to include ELXR epigenetic silencing technology.The Motley FoolCathie Wood Bought Just 3 Stocks On Monday; Here They AreArk Invest added to positions in Nvidia, SoFi Technologies, and Scribe Therapeutics on Monday. Nvidia fell 4% on a CEO scandal, SoFi rose 3.33% after a 41% annual drop, and Scribe Therapeutics gained 6% despite a 22% yearly decline.